ArticleClinical & translational immunology2017
Understanding CD8
Article in Clinical & translational immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- HLA-B*15:01-positive severe COVID-19 patients lack CD8Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens.Current oncology (Toronto, Ont.) · 2024Article
- CD8Nature communications · 2024Article
- Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.Nature immunology · 2023Article
- SARS-CoV-2-specific CD8Immunology and cell biology · 2021Article
- Review
- CD8Science immunology · 2021Article
- Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients.Nature communications · 2021Article
- Suboptimal SARS-CoV-2-specific CD8Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells.PLoS pathogens · 2020Article
- The ABC of Major Histocompatibility Complexes and T Cell Receptors in Health and Disease.Viral immunology · 2020Review
- Challenging immunodominance of influenza-specific CD8Nature communications · 2019Article
- Identification ofBiomarker research · 2019Article
- Broad CD8Nature communications · 2018Article
- Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8Frontiers in immunology · 2018Article
- Single-Cell Approach to Influenza-Specific CD8Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.